Various clinical and laboratory observations suggest that the leukaemia cells in chronic myeloid leukaemia (CML) are potentially immunogenic. Whilst the ability of the leukaemia cells to elicit an anti-leukaemic immune response in the allogeneic setting is established, it remains unclear why such anti-leukaemic response does not occur in vivo in the autologous setting. We previously demonstrated the presence of leukaemia-reactive T cells in a patient with CML. However, we found that the T cells were normally anergic unless pre-incubated in vitro in highdose recombinant interleukin-2. We speculated that the T cell anergy was the result of a lack of the appropriate immune costimulatory molecules on the leukaemia cell surface. In this study, we confirm the absence of immune costimulatory molecules, CD80 (B7-1) and CD86 (B7-2), on leukaemia cells and demonstrated that these costimulatory molecules on the leukaemia cells can be upregulated by a combination of GM-CSF and IL-4. There was an associated restoration of leukaemia cell immunogenicity to autologous T cells in mixed lymphocyte leukaemia reactions, suggesting a possible enhancement of antileukaemic reaction. More importantly, T cells primed with 'activated' leukaemia cells were able to recognise fresh cytokinenaive leukaemia cells. Furthermore, leukaemia cells expressing the dendritic cell marker, CD1a, were also generated. Our findings therefore suggest the opportunity in future to use these combination cytokines in vivo or these leukaemia cells which have been activated in vitro for leukaemia immunotherapy.
Introduction
T cell immunity may play a fundamental role in the control of leukaemia cell growth in CML. Previous works have demonstrated that patients receiving T-depleted allogeneic bone marrow transplants (BMT) have a significantly higher risk of leukaemia relapse than those who received unmanipulated bone marrows. 1, 2 Furthermore, leukaemia remission can be induced by infusions of donor lymphocytes to patients who relapsed following allogeneic BMT. 3 These studies therefore provide evidence of the T cell immunogenicity of the leukaemia cells in the allogeneic BMT setting.
Whilst some of the anti-leukaemia effect of allogeneic BMT arises as part of a more global graft-versus-host reaction (GVH) due to minor histocompatibility between the donor and the recipient, it is likely that additional leukaemia eradication is mediated through effector cells directed at specific leukaemia antigens. 4 The presence of such a T cell population has been dissected from the GVH effect in studies involving the autologous hosts. The immunogenicity of leukaemia cells in the autologous setting has been supported by the demonstration that, not unlike tumour infiltrating lymphocytes in solid, repertoire of TCR V␤ gene usage by T cells associated with CML was restricted when compared to those in normal healthy individuals. 5 Furthermore, leukaemia-reactive T cells could be isolated from the autologous host in CML, either de novo 6 or following autologous peripheral blood stem cell transplantation. 7 However, although leukaemia-reactive MHC-depen- dent T cells could be isolated in these patients, 6 such an antileukaemic response was ineffective in vivo in the autologous setting because the T cells were anergic. When the T cell anergy was reversed by pre-incubation in vitro of T cells with high-dose interleukin-2 (IL-2), these T cells proliferated and produced interferon-␥ in mixed lymphocyte leukaemia reactions. They also lysed fresh autologous leukaemia cells.
There are many possible reasons why T cell anergy to leukaemia cells occurs. However, the likeliest cause is the lack of the appropriate immune costimulatory molecules on the leukaemia cells which could provide the second signal needed for optimal T cell activation. De novo tumour cells do not express T cell costimulatory molecules. Transfection 8, 9 or induction by cytokines 10 of tumour cells to express CD80/CD86 resulted in T cell responses to these tumours, supporting the importance of these costimulatory molecules in eliciting effective T cell responses. In this study, we confirm that CD80 and CD86 are absent on CML cells. We demonstrate that it was possible to upregulate the expression of these molecules by a combination of cytokines. Expression of these molecules was associated with an enhancement of T cell reactivity to the autologous leukemia cells.
Materials and methods

Isolation of peripheral blood mononuclear cells (PBMC)
Peripheral blood from six untreated patients with CML was collected into heparin and the PBMC isolated using Histopaque (Sigma, Poole, UK) density gradient centrifugation. Light density cells were harvested, washed three times in phosphate-buffered saline (PBS) and resuspended in RPMI 1640 medium supplemented with 10% fetal calf serum before being used for subsequent experiments.
Cytokine induction of costimulatory molecules PBMC were washed and cultured in RPMI 1640 (Life Technologies, Gibco, Paisley, UK) supplemented with 10% fetal calf serum at 37°C with 5% CO 2 . Various cytokines (interleukin-1 (IL-1); IL-4; IL-6; GM-CSF and PMA) were added individually or in combinations. Cultured cells were immunophenotyped between 5-7 days of culture by fluoro-cytometry using a cocktail of antibodies.
Immunophenotyping
This was carried out on all the cultured cells using a fluorescence-activated cell scan (FACScan; Becton Dickinson, CA, USA) and analysed by Lysis II programme. Monoclonal antibodies used were: PE-conjugated mouse anti-human CD1a (Serotec, UK) and CD80 (B7-1; Becton Dickinson, UK) and FITC-conjugated mouse anti-human CD86 (B7-2; Serotec), CD11c, CD14, CD3 and HLA-DR antibodies (Becton Dickinson). One stage direct staining was carried out. Briefly, the cells were first washed twice in wash buffer (PBS + 2% bovine serum albumin and 0.5% sodium azide). Antibody at manufacturer's recommended concentrations was added to each cell pellet and the cells were incubated on ice for 30-40 min before being washed three times and resuspended in 2% paraformaldehyde solution ready for analysis.
Fluorescence in situ hybridisation (FISH) analysis FISH was performed on cytospin preparations of fluorescence sorted cells fixed in 3:1 methanol:glacial acetic acid fixative. In situ DNA was denatured in 70% formamide, 2 × SSC, pH 5.3 at 72°C for 2 min followed by sequential dehydration at room temperature (70%, 80%, 90% and 100% ethanol for 2 min each) and air drying.
The presence of bcr-abl positive CD1a + cells was determined by signal co-localisation of the dural colour LSI bcrabl probe (Vysis, IL, USA). The probe was hybridised in 65% formamide, 10% dextran sulphate and 2 × SSC, pH 5.3. After denaturation for 5 min at 75°C, 10 l of probe was added to the denatured cytospin preparations. After overnight hybridisation at 37°C, the cytospin slides were washed in 0.4 × SSC, pH 5.3 for 2 min followed by a 1-min wash in 2 × SSC, pH 5.3 with 0.1% NP-40. The slides were air dried, counter-stained with DAPI (Vysis) and visualised on a fluorescence microscope.
T cell proliferation assays
Responder cells were seeded into 96-well microtitre plates in the presence of varying concentration of stimulator cells which had been irradiated at 4000 rads. Cultures were set up in RPMI 1640 medium supplemented with 10% fetal calf serum and incubated at 37°C in 5% CO 2 for 5 days. Cells were pulsed with 0.5 Ci tritiated methyl-thymidine ( 3 Hthymidine) 18 h prior to harvesting onto glass fibre filters.
3 Hthymidine uptake was measured by liquid scintillation using a ␤ counter and expressed as the mean counts per minutes (c.p.m.) of triplicates.
Results
Absence of surface costimulatory molecules on leukaemia cells
We first determined the expression of CD80 and CD86 on leukaemia cell surface. There was a universal absence of CD80 and CD86 costimulatory molecules on the leukaemia cell surface in all of the CML PBMC analysed (data not shown). These results therefore suggest that the absence of these costimulatory molecules may play a part in the T cell anergy to leukaemia cells observed in CML.
Cytokine induction of costimulatory molecules
To induce the expression of CD80 and CD86, fresh leukaemia cells were cultured in varying concentrations and combinations of IL-1, IL-4, IL-6, GM-CSF and PMA. Using every possible combination and to a maximum final concentration of 20 ng/ml of each cytokine, no significant expression of the costimulatory molecules was observed (data not shown). However, when the GM-CSF and IL-4 doses were increased to 250-500 ng/ml and 40 ng/ml, respectively, and the cytokine cocktail used on adherent leukaemia cells, we observed that they significantly upregulate the expression of CD80 and CD86 on the surface of the five of six leukaemia cell populations (Figure 1 ). There were also corresponding increases in the expression of HLA-DR antigens. Further immunophenotyping also indicated that some of the total cultured cells were expressing the dendritic cell marker of CD1a (Figure 1) . The CD1a + cells ranged from 0.8% to 53% of the cell population. To determine the origin of these dendritic-like CD1a + cells, CD1a
+ cells from two patients were sorted from the bulk culture and analysed by FISH using the bcr-abl-specific probe. 15/15 (100%) and 10/10 (100%) cells showed signal co-localisation. Given that co-localisation occurs by chance in only 5-10% of normal cells, these results suggest that up to 100% of all the cells analysed were bcr-abl-positive and have derived from the leukaemic clone ( Figure 2 ).
Increased immunogenicity of leukaemia cells to donor lymphocytes
The upregulation of these costimulatory molecules may be associated with an enhancement of the immunogenicity of the leukaemia cells. We therefore determined if the cytokine preincubation enhances the immunogenicity of the leukaemia cells to HLA-mismatched donor lymphocytes. This was determined by mixed allo-lymphocyte leukaemia reactions. In contrast to normal leukaemia cells, leukaemia cells pre-incubated in IL-4 and GM-CSF were much more efficient than native leukaemia cells when used as stimulator cells in generating T cell proliferative responses in HLA-mismatched donors (Figure 3) . The proliferation indices increased by 2.5-to 9-fold.
Enhancement of mixed lymphocyte leukaemia reactions
Since GM-CSF/IL-4 pre-incubated leukaemia cells were more immunogenic than cytokine-naive leukaemia cells in the allogeneic setting, we proceeded to determine if a similar enhancement of immunogenicity could occur to autologous T cells. In keeping with our previous study, 6 the proliferation indices of T lymphocytes to irradiated cytokine-naive autologous leukaemia cells was low, between 1.5-2. However, following cytokine pre-incubation, autologous T cells were able to increase their proliferation in response to irradiated leukaemia cells in five of the six tested samples (Figure 4) . The proliferation indices increased by 1.7-to 6.3-fold. In general, improvement in the proliferation indices was seen in those leukaemia cells with a higher expression of CD80/CD86 molecules whilst the proliferation index was only minimally elevated in the one patient in whom the induction of costimulatory molecules was suboptimal. To determine the relevance of this immune response in the context of fresh leukaemia cells, T cells primed with the CD80/CD86
+ leukaemia cells were cocultured with cytokine-naive leukaemia cells. T cells were able to proliferate in response to stimulation with the cytokine-naive leukaemia cells, suggesting that these T cells recognised epitopes on the cytokine-naive leukaemia cells Interphase FISH analysis of CD1a + leukaemia cells using bcr-abl-specific probe, showing co-localisation (yellow) of the bcr (blue) and abl (red) signal. which had been presented by the CD80/CD86 + leukaemia cells.
To exclude the possibility that the increase in proliferation was secondary to T cell responses to an exogenous antigen (eg FCS) introduced during cell culture, proliferation assays were carried out in five normal donors using autologous GM-CSF/IL-4 pre-incubated PBMC. Despite many more cells (average 40%) expressing the CD1a, CD80 and CD86 markers, no significant increase in the T cell proliferation was observed (Figure 4) , except in one sample. Furthermore, similar improvement of T cell proliferation to cultured autologous leukaemia cells was also observed when FCS was substituted with human AB serum (data not shown). These results therefore suggest that the increase in the proliferation indices of T cells to autologous leukaemia cells were leukaemia-related.
Discussion
To trigger optimal T cell responses, two signals are required. The first signal is mediated via TCR which binds to the antigenic peptides associated with MHC and the second signal through CD28 and CTLA4 which interact with the costimulatory molecules, CD80 and/or CD86, on the antigenpresenting cells. Costimulatory signals are neither antigen-specific nor MHC-restricted and result in T cell proliferation, cytokine release and effector function. Failure of the second signal due to the absence of these costimulatory molecules or blocking of the receptors results in T cell anergy and/or deletion. Therefore, even if a tumour cell could process and present a tumour antigen to the T cell repertoire, effective antitumour responses could only occur if the tumour cells are equipped to provide the second activation signal. The importance of this activation pathway is becoming increasingly recognised in the pathophysiology of tumour immunity. In this study, we therefore set out to investigate if the T cell anergy, we previous reported in CML, 6 was associated with an absence of CD80/CD86 on the leukaemia cell surface. We reasoned that if these costimulatory molecules were absent, it may be possible to upregulate their expression using cytokines. Furthermore, it may be possible to determine if the upregulation of these molecules is associated with improved immunogenicity of the leukaemia cells, both in the allogeneic and autologous setting.
We demonstrated that, not unlike solid tumour cells, CML cells do not express the CD80/CD86 costimulatory molecules. Absence of these molecules may therefore contribute towards the induction of anergy in leukaemia-reactive T cells and the failure to evoke clinically significant T cell-mediated anti-leukaemia immunity. The failure of the immune responses was also reflected in the low proliferation indices of autologous T cells when cocultured with irradiated leukaemia cells.
In order to improve the immunogenicity of the leukaemia cells, we attempted to upregulate the surface expression of these costimulatory molecules on the cells. It was found that using a combination of GM-CSF and IL-4 in a protocol as for the generation of dendritic cells from peripheral blood mononuclear cells, 11 leukaemia cells were able to express CD80/CD86 molecules after 7-10 days of culture in vitro. This was also associated with increases in the expression of HLA-DR molecules. Interestingly, there was also corresponding expression in some cells of the dendritic cell markers, CD1a. These 'dendritic cells' were found to be of leukaemia origin, as determined by FISH analysis using the bcr-abl-specific probe.
It remains speculative why these costimulatory molecules are not expressed constitutively on leukaemia cells in vivo. Whilst there is a long list of possible reasons for the failure to express CD80/CD86 by the leukaemia cells, the ability to induce these costimulatory molecules in vitro would suggest that the microenvironment of the leukaemia cells does not promote such development. The unfavourable microenvironment may be the result of associated immune inhibitory cytokines in the serum. It would therefore be interesting in future to investigate the effect of patient's serum on the induction of these surface costimulatory molecules.
The increased expression of the immune costimulatory molecules was associated with improvement in the immunogenicity of the leukaemia cells to autologous T cells, as determined by the mixed lymphocyte leukaemia reactions, either in the autologous or allogeneic settings. Such T cell helper responses may confer a potentially beneficial anti-leukaemia effect. It is also possible that the increased HLA-DR expression on the leukaemia cells may play a part in increasing the leukaemia cell immunogenicity because of the increased copy number of tumour peptide expressed in association with the MHC class II molecules.
Two recent studies 12, 13 showed that it was possible to generate leukaemic dendritic cells from patients with CML. These dendritic cells were potent stimulators of lymphocyte proliferation and autologous T cells stimulated with the dendritic cells displayed strong cytotoxic activity against CML cells. Our study therefore provides another dimension to improving the immunogenicity of leukaemia cells. Instead of using CD34-selected cells 12 or a three cytokine combination, 13 we used adherent peripheral blood mononuclear cells incubated con-currently with GM-CSF and IL-4 only. This resulted in the upregulation of CD80/CD86 molecules on the leukaemia cell surface with an associated enhancement of the immunogenicity. Whilst the expression of these costimulatory molecules may be achieved with gene transfection, CD80 expression on the leukaemia cells induced by the cytokine combination was much higher than those achieved using a retroviral vector (unpublished data) because of the low gene transfer efficiency which occurs due to the low number of cells in the cell cycle. Therefore, GM-CSF/IL-4 cytokine combination for the induction of costimulatory molecule expression by peripheral CML cells may offer an alternative method to improving the immunogenicity of the leukaemia cells.
Specific tumour immunotherapy relies on the identification and targeting of tumour-specific or associated antigens. In CML, there are many potential leukaemia antigens which may be suitable for immune targeting. The most widely studied antigen is the bcr-abl fusion peptide which have been shown to elicit T cell proliferative and cytotoxic [14] [15] [16] responses. However, clinical success in cancer immunotherapy probably requires polyclonal responses and poly-antigenic targeting. Therefore these in vitro generated immunogenic leukaemia cells may serve as an ideal vehicle of immunotherapy without having to identify the specific leukaemia antigens. It may also be possible to use the IL-4/GM-CSF combination cytokine in vivo, although whether or not similar upregulation of costimulatory molecules could be achieved in vivo requires to be determined.
